Amicus Therapeutics Inc., of Cranbury, N.J., said it completed a $25 million long-term debt financing with a lending syndicate consisting of Midcap Financial LLC, Oxford Finance LLC and Silicon Valley Bank. The company has already drawn down $15 million under this facility, and a second tranche of $10 million will be available through the end of 2014. Amicus projected that its current cash position, including the proceeds from a private placement and the debt financing, will be sufficient to fund operations into the second half of 2015. The company recently raised $15 million in a private placement of 7.5 million shares of common stock priced at $2 per share, plus the issuance of warrants to purchase an additional 1.6 million shares at $2.50 per share. The company is planning to use the proceeds from the transactions to advance the development of therapies for Fabry, Pompe and other lysosomal storage diseases using its chaperone-advanced replacement therapy platform technology.

Redhill Biopharma Ltd., of Tel Aviv, Israel, said it entered a definitive agreement with Orbimed Israel Partners Ltd. Partnership, an affiliate of Orbimed Advisors LLC, for the sale of their American Depository Shares and warrants in a $6 million private placement transaction. As well as general working capital some of the proceeds will be used for the clinical development of their lead combination oral antibiotic therapies in gastrointestinal programs: They include RHB-104 for Crohn’s disease and RHB-105 for H. pylori infection, both currently undergoing Phase III studies in the U.S.